www.managedhealthcareexecutive.com
Open in
urlscan Pro
76.76.21.22
Public Scan
URL:
https://www.managedhealthcareexecutive.com/
Submission: On January 10 via api from IE — Scanned from DE
Submission: On January 10 via api from IE — Scanned from DE
Form analysis
2 forms found in the DOM<form class="form-inline"><input type="text" placeholder="Search" value="" class="form-control"><button style="background-color:var(--secondary);border:none" type="button" class="btn btn-primary">Search</button></form>
<form class="form-inline"><input type="text" placeholder="Search" value="" class="form-control"><button style="background-color:var(--secondary);border:none" type="button" class="btn btn-primary">Search</button></form>
Text Content
CONTINUE TO SITE OR WAIT null SECS Advertisement * * * * Search Resource Centers View MoreAsthmaAtrial FibrillationBiosimilarsBlood CancerCovid-19DermatologyDigital HealthEye CareHemophiliaHIVLiver DiseaseMultiple SclerosisPost-Acute CarePrescription Digital TherapeuticsRespiratory ConditionsSleep DisordersSubstance Use DisorderType II InflammationUlcerative Colitis AsthmaAtrial FibrillationBiosimilarsBlood CancerCovid-19DermatologyDigital HealthEye CareHemophiliaHIVLiver DiseaseMultiple SclerosisPost-Acute CarePrescription Digital TherapeuticsRespiratory ConditionsSleep DisordersSubstance Use DisorderType II InflammationUlcerative Colitis Spotlight AMCP AnnualAsembia’s 2022 Specialty Pharmacy SummitAMCP NexusExamining Evolving Treatment Paradigms in the Hemophilia B Space Payer Provider Perspectives: Prescription Digital Therapeutics: Reimagining Care in Behavior-Driven ConditionsPBMI National ConferenceUnbranded Biologics: An Overview AMCP AnnualAsembia’s 2022 Specialty Pharmacy SummitAMCP NexusExamining Evolving Treatment Paradigms in the Hemophilia B Space Payer Provider Perspectives: Prescription Digital Therapeutics: Reimagining Care in Behavior-Driven ConditionsPBMI National ConferenceUnbranded Biologics: An Overview Business View MoreBusiness StrategyChronic DiseaseConsumersDrug CostsDrug PipelineFormularyHealth ManagementHealth/Disease StrategyHospitals & ProvidersIndustry AnalysisPharmacyPolitics and PolicyPractice ManagementReimbursementTechnology Business StrategyChronic DiseaseConsumersDrug CostsDrug PipelineFormularyHealth ManagementHealth/Disease StrategyHospitals & ProvidersIndustry AnalysisPharmacyPolitics and PolicyPractice ManagementReimbursementTechnology News Media Expert Interviews K-Cast Medical World News Podcasts Population Health Perspectives Expert InterviewsK-CastMedical World NewsPodcastsPopulation Health Perspectives ConferencesPartners Publications MHE Publication Supplements And Featured Publications MHE PublicationSupplements And Featured Publications Events Virtual Events Virtual Events CME/CE Resources PBM Leaders Sponsored Sponsored Content Surveys PBM LeadersSponsoredSponsored ContentSurveys Subscribe eNewsletter Print Subscription eNewsletterPrint Subscription * Advertise * Editorial * Contact Us * Terms and Conditions * Privacy * Do Not Sell My Personal Informations * © 2023 MJH Life Sciences and Managed Healthcare Executive. All rights reserved. Search Advertisement Resource CentersSee All > * Asthma * Atrial Fibrillation * Biosimilars * Blood Cancer * Covid-19 * Dermatology * Digital Health * Eye Care * Hemophilia * HIV * Liver Disease * Multiple Sclerosis * Post-Acute Care * Prescription Digital Therapeutics * Respiratory Conditions * Sleep Disorders * Substance Use Disorder * Type II Inflammation * Ulcerative Colitis Spotlight * AMCP Annual * Asembia’s 2022 Specialty Pharmacy Summit * AMCP Nexus * Examining Evolving Treatment Paradigms in the Hemophilia B Space * Payer Provider Perspectives: Prescription Digital Therapeutics: Reimagining Care in Behavior-Driven Conditions * PBMI National Conference * Unbranded Biologics: An Overview BusinessSee All > * Business Strategy * Chronic Disease * Consumers * Drug Costs * Drug Pipeline * Formulary * Health Management * Health/Disease Strategy * Hospitals & Providers * Industry Analysis * Pharmacy * Politics and Policy * Practice Management * Reimbursement * Technology Advertisement * Advertise * Editorial * Contact Us * Terms and Conditions * Privacy * Do Not Sell My Personal Informations * * © 2023 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved. RISK OF COVID-19 MAY INCREASE FOR VACCINATED DEPENDING ON TIME OF LAST CONTRACTION January 10th 2023 Researchers at Cleveland Clinic evaluated whether a bivalent COVID-19 vaccine protects against both strains of the virus - the original virus strain and a component of the omicron variant. ENGINEERED PROBIOTICS TARGET PROINFLAMMATORY MOLECULES AND IMPROVE ULCERATIVE COLITIS SYMPTOMS January 9th 2023 Stomach acid interferes with the effectiveness of probiotics taken as pills. Researchers are bioengineering probiotics in hopes of getting around that problem. AI MAY BE ABLE TO HELP DIAGNOSE OSTEOARTHRITIS EARLY January 9th 2023 Artificial intelligence can locate tibial spiking in x-ray images, which many believe to be an early sign of knee osteoarthritis. HEART RATE, MOVEMENT MAY USED TO PREDICT VO2 MAX January 9th 2023 Researchers investigated whether it might be possible to use AI and machine learning to develop a model that could use data from everyday activity (rather than workouts) to accurately predict VO2max. CUSTOM HEALTH, L.A. CARE TEAM UP ON ADHERENCE PILOT January 9th 2023 Custom is one of the growing number of companies focusing on adherence. It changed its name from Pack4U last year. Advertisement Advertisement ENSURE YOU PARTNER WITH PROBLEM SOLVERS, NOT PROBLEM FINDERS January 08, 2023 ByAndrew Perlstein What’s more valuable than the ability to identify problems within your business plan or strategy? The ability to find solutions to those problems before they arise. FDA UPDATES FOR THE WEEK OF JAN. 3, 2023 January 07, 2023 ByDenise Myshko The FDA ends the week with the approval of the Alzheimer’s medication lecanemab. Two other approvals include: Olpruva for urea cycle disorders and Wegovy for weight loss in teens. The agency has also accepted several applications, including Genentech’s second bispecific antibody, glofitamab, for blood cancer, UCB’s second application for generalized myasthenia gravis, and a therapy RSV prevention in infants. Two companies have submitted applications: Celltrion for a new formulation of infliximab and Orasis for blurry vision treatment. FDA APPROVES NEW ALZHEIMER'S DRUG, LEQEMBI. CAN IT ESCAPE ADUHELM'S FATE? January 07, 2023 Leqembi's starting price is almost half of what Aduhelm's was and the FDA-approved label narrows use to people with early disease. But Medicare coverage restrictions may still apply and there is concern about a side effect called ARIA (amyloid related imaging abnormalities). BIPARTISAN AGREEMENT ON HEALTH POLICY IS POSSIBLE January 06, 2023 Experts say Democrats and Republicans could work together on telehealth, mental health and physician payment issues in 2023. FOR ALS TREATMENTS, THREE GENES ARE TARGETS January 05, 2023 Dozens of gene mutations associated with amyotrophic lateral sclerosis have been identified. Drug developers have homed in on a trio of genes. Next >> Advertisement Advertisement Advertisement x × We Value Your Privacy Settings NextRoll, Inc. ("NextRoll") and our advertising partners use cookies and similar technologies on this site and use personal data (e.g., your IP address). If you consent, the cookies, device identifiers, or other information can be stored or accessed on your device for the purposes described below. You can click "Allow All" or "Decline All" or click Settings above to customize your consent. NextRoll and our advertising partners process personal data to: ● Store and/or access information on a device; ● Create a personalized content profile; ● Select personalised content; ● Personalized ads, ad measurement and audience insights; ● Product development. For some of the purposes above, our advertising partners: ● Use precise geolocation data. Some of our partners rely on their legitimate business interests to process personal data. View our advertising partners if you wish to provide or deny consent for specific partners, review the purposes each partner believes they have a legitimate interest for, and object to such processing. If you select Decline All, you will still be able to view content on this site and you will still receive advertising, but the advertising will not be tailored for you. You may change your setting whenever you see the Manage consent preferences on this site. Decline All Allow All Manage consent preferences